Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O43167
UPID:
ZBT24_HUMAN
Alternative names:
Zinc finger protein 450
Alternative UPACC:
O43167; Q17RC6; Q5TED5; Q8N455
Background:
Zinc finger and BTB domain-containing protein 24, alternatively known as Zinc finger protein 450, plays a crucial role in the biological system, potentially involved in BMP2-induced transcription. This protein's unique structure and function underscore its significance in cellular processes.
Therapeutic significance:
Linked to Immunodeficiency-centromeric instability-facial anomalies syndrome 2, a rare disorder characterized by immunodeficiency and genomic instability, Zinc finger and BTB domain-containing protein 24's study could lead to novel therapeutic interventions for managing this complex syndrome.